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a b s t r a c t
Replication-competent latent HIV-1 proviruses that persist in the genomes of a very small subset of
resting memory T cells in infected individuals under life-long antiretroviral therapy present a major
barrier towards viral eradication. Multiple molecular mechanisms are required to repress the viral trans-
activating factor Tat and disrupt the regulatory Tat feedback circuit leading to the establishment of the
latent viral reservoir. In particular, latency is due to a combination of transcriptional silencing of
proviruses via host epigenetic mechanisms and restrictions on the expression of P-TEFb, an essential co-
factor for Tat. Induction of latent proviruses in the presence of antiretroviral therapy is expected to
enable clearance of latently infected cells by viral cytopathic effects and host antiviral immune responses.
An in-depth comprehensive understanding of the molecular control of HIV-1 transcription should inform
the development of optimal combinatorial reactivation strategies that are intended to purge the latent
viral reservoir.
& 2014 Elsevier Inc. All rights reserved.
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Introduction
Potent combination antiretroviral therapy (HAART) can effec-
tively block viral replication in the host and reduce the circulating
virus to undetectable levels. Although patients adhering to the
HAART regimen have minimal viremia, HIV persists due to the
existence of latent but replication-competent proviruses in a very
small population of resting memory CD4þ T cells (1 in 106 cells)
in peripheral blood (Finzi et al., 1999) and tissues (Yukl et al.,
2010). Viral persistence during antiretroviral therapy has also been
attributed to ongoing low-level viral replication in anatomical
sanctuary sites (e.g. gut-associated lymphoid tissues, other lym-
phoid tissues, genital tract and the central nervous system) that
may be comparatively inaccessible to drugs (Cory et al., 2013;
Palmer et al., 2011).
In virtually all patients, when HAART is interrupted circulating
HIV levels rebound within 2 to 8 weeks and uncontrolled replica-
tion resumes (Chun et al., 1999; Stöhr et al., 2013) although a few
rare patients are able to spontaneously control their infections
(Sáez-Cirión et al., 2013). However, residual virus recovered from
treated patients (Brennan et al., 2009), and the rebounding virus
recovered during the short treatment interruptions (Joos et al.,
2008), have much less sequence heterogeneity than seen in
actively replicating viral populations, suggesting that replenish-
ment of the viral population arises from reactivation of a very
restricted set of latently infected cells. HIV-1 subsets in the GALT of
patients under HAART initiated at the acute phase have low
diversity, suggesting highly restricted viral replication in this
anatomical compartment (Evering et al., 2012).
HIV-1 infects CD4þ T lymphocytes, and to a lesser extent,
myeloid cells including perivascular macrophages, microglia,
astrocytes and dendritic cells in the brain. Both T-cells and myeloid
cells can establish latent infections (Marban et al., 2007; Wires
et al., 2012). Latently infected T-cells are usually established during
the acute phase (Chun et al., 1998), are undetectable by host
immune surveillance, are extremely stable (t1/244 months)
(Siliciano et al., 2003, 2007), and can be replenished through
homeostatic proliferation (Chomont et al., 2009).
The latent viral reservoir has therefore proven to be the major
obstacle towards ﬁnding a sterilizing cure or even a functional
cure for HIV-1 infection. As part of current efforts to identify a
broad-based cure for HIV infection, research has focused on
identifying drugs capable of inducing latent HIV reservoirs with-
out causing deleterious host systemic inﬂammatory responses
(“shock”). Reactivation of proviruses in the presence of HAART is
expected to make them visible to the immune system and lead to
the clearance of latently infected cells (“kill”). For instance, a
recent promising study by Shan et al. demonstrated that latently
infected resting CD4þ T cells treated with the histone deacetylase
inhibitor SAHA to reactivate proviral gene expression were sus-
ceptible to efﬁcient killing in vitro by HIV antigen-speciﬁc CD8þ T
cells (Shan et al., 2012).
This article will review our knowledge of these intricate
mechanisms involved in the establishment and maintenance of
latent HIV infections and how these insights are informing the
development of therapies that are intended to purge latent HIV
reservoirs. Over the last 20 years numerous factors involved in the
regulation of HIV transcription have been identiﬁed. To help the
reader, Table 1 provides a glossary and overview of the key factors
referred to in this review.
Regulation of HIV transcription by Tat
Control of latency by the Tat feedback mechanism
There are no speciﬁc repressors of proviral transcription
encoded by HIV. Instead, the entry into latency is a consequence
of multiple cellular restrictions at the promoter and elongation
phase of viral transcription that ultimately repress expression of
the viral trans-activating factor Tat and disrupt the positive
regulatory Tat feedback circuit (Fig. 1) (Karn, 2011). In particular,
transcriptional silencing of proviruses via epigenetic and non-
epigenetic mechanisms, and regulation of the essential
Tat-cofactor P-TEFb, are critical for the establishment and main-
tenance of latent infections.
The vast majority of productive HIV infections occur in acti-
vated, or at least partially activated, T-cells. Activated effector
CD4þ T cells have an intracellular environment that makes them
highly permissive for productive infection by HIV (Siliciano and
Greene, 2011), however, the transition of infected effector cells to a
resting memory phenotype substantially diminishes transcription
initiation at the HIV LTR which enables the establishment of
transcriptionally silent proviruses. Following re-stimulation,
latently infected resting memory CD4þ T-cells convert to a
permissive intracellular environment with high levels of P-TEFb
and transcription initiation factors in the nucleus. The central role
of the Tat feedback regulatory mechanism to reactivate HIV from
latency is clearly demonstrated by two observations: First, expres-
sion of Tat in trans from an ectopic promoter prevents viral entry
into latency (Pearson et al., 2008); and second, latent proviruses
encoding a functionally defective Tat mutant (C22G) can initiate
transcription following T-cell activation but are absolutely defec-
tive for viral gene expression (Kim et al., 2011).
Structure and function of the proviral long terminal repeat
The U3 and R regions of the proviral 50 long terminal repeat (LTR)
act as the viral promoter. Although both the 50 LTR and 30 LTR have
identical sequences, concomitant transcription from the 30 LTR is
highly inefﬁcient due to interference of its U3 region by positive-
sense transcribing complexes that terminate RNA synthesis at the
R/U5 junction (Cullen et al., 1984; Gallastegui et al., 2011).
The viral core promoter comprises three tandem Sp1 binding
sites, a TATA box, and an initiator element at the transcription start
site. The enhancer and modulatory regions of the LTR contain cis-
acting recognition elements for regulatory cellular transcription
factors. Speciﬁcally, NF-κB p65/p50 heterodimers, NFAT, STAT5
and AP-1 have been identiﬁed as signal-dependent positive
regulators of HIV transcription initiation (Kinoshita et al., 1997;
Nabel and Baltimore, 1987; Selliah et al., 2006; Yang et al., 1999).
Immediately downstream of the transcription start site is the
TAR sequence which encodes an RNA stem-loop structure that is
directly bound by Tat in order to mediate recruitment of a cellular
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elongation factor complex that stimulates efﬁcient transcription
elongation (Dingwall et al., 1990; Kao et al., 1987).
Transcriptional pausing of RNAPII at the proviral LTR
One of the most insightful recent advances in studies of transcrip-
tional control is that the majority of mammalian protein-encoding
genes carry poised RNAP II in the promoter proximal region (Core and
Lis, 2008). The paused RNAP II permits rapid responses to transcription
signals. Not surprisingly, recent studies from our laboratory have
shown that latent HIV proviruses is also always primed for rapid
transcriptional responses due to promoter proximal pausing of RNAP II
(Jadlowsky et al., 2014) (Fig. 2A). Promoter proximal pausing accounts
for the characteristic formation of short transcripts of 60 nucleotides
that accumulate following processing of the nascent transcripts
produced by abortive RNAP II escape (Laspia et al., 1989) and is seen
in both actively transcribing and latently infected cells. Recently,
Wagschal et al. (2012) have proposed that the short transcripts are
Table 1
Host factors involved in the regulation of HIV proviral transcription.
Factor or complex Description Reference
Initiation
Sp1 Required for assembly of the pre- initiation complex at the LTR TATA box. Co-operatively interacts
with NF-κB p65/p50
Perkins et al. (1993)
TFIIH Component of the pre-initiation complex whose recruitment to the HIV LTR is NF-κB-dependent.
Stimulates RNAPII to clear the promoter and initiate transcription
Kim et al. (2006)
NF-kB (p65/p50) Central to the signal-dependent activation of HIV transcription initiation. Enables recruitment
of histone acetyltransferases (HATs) to the LTR
Nabel and Baltimore (1987) Gerritsen
et al. (1997)
NFAT Calcium-dependent activator of HIV transcription initiation. NFAT recognition sequences on the viral
promoter overlap with NF-κB elements
Chan et al. (2013) Gifﬁn et al. (2003)
AP-1 Nuclear complex of c-fos and c-jun that is formed upon T-cell activation and can directly bind the HIV
LTR and enhance NF-κB activity
Yang et al. (1999)
Repression
LSF/YY1 Cooperative recruitment of LSF and YY1 to the LTR enables repression via recruitment of HDAC1 He and Margolis (2002)
CBF-1 CBF1 interacts with the LTR and represses proviral transcription by facilitating recruitment of HDAC1
and its co-repressor subunits CIR and mSin3A
Tyagi and Karn (2007) Tyagi et al. (2010)
p50/p50 Binding of p50 homodimers to the κB elements permits recruitment of HDAC1 Williams et al. (2006)
E2F1 Can partner with p50 to bind κB elements and suppress transcription initiation, probably by recruiting
BRD2
Kundu et al. (1997) Karn (2013)
CTIP2 Suppresses HIV transcription initiation in microglial cells in cooperation with COUP-TF and Sp1.
Recently identiﬁed as a regulatory component of 7SK snRNP in T-cells
Marban et al. (2007) Cherrier et al. (2013)
BRD2 Present at the promoter of latent proviruses. Suppresses proviral transcription initiation, possibly
through an interaction with E2F1
Boehm et al. (2013) Karn (2013)
Chromatin modiﬁcation
HDACs Histone deacetylases HDAC1, HDAC2, and HDAC3 are each involved in establishment and maintenance
of HIV latency
Keedy et al. (2009)
HATs The histone acetyltransferases p300/CBP and P/CAF reverse chromatin blocks and are recruited to the
viral promoter by NF-κB and NFAT
Gerritsen et al. (1997)
SUV39H1 Trimethylates histone H3 Lys9 (H3K9me3), an epigenetic marker of HIV latency du Chene et al. (2007)
G9a Dimethylates histone H3 Lys9 (H3K9me2) Imai et al. (2010)
EZH2 Histone methyltransferase component of PRC2. Responsible for histone H3 Lys27 trimethylation
(H3K27me3) found on silenced proviral templates
Friedman et al. (2011)
DNMT1 Methylates CpG islands at the HIV LTR Blazkova et al. (2012)
Chromatin remodeling
BAF SWI/SNF chromatin remodeling complex which positions proviral Nuc-1 to repress transcription Rafati et al. (2011)
PBAF Replaces BAF at the viral LTR to remodel Nuc-1 and enable transcription Rafati et al. (2011)
Promoter-proximal pausing
DSIF Heterodimer of hSpt4 and hSpt5 which interacts with RNAPII, mRNA capping enzyme, and nascent
RNA. Stimulates 50 RNA capping and recruitment of NELF. Phosphorylation of hSpt5 by P-TEFb
transforms DSIF into a positive elongation factor
Yamaguchi et al. (2002)
NELF Heterotetramer that binds TAR RNA and a preformed DSIF/RNAPII complex. Induces premature
termination and formation of a stable RNAPII paused complex
Pagano et al. (2014) Yamaguchi et al.
(2002)
Microprocessor Processes TAR RNA leading to recruitment of Setx, Xrn2, and Rrp6. These factors cooperatively
induce RNAPII pausing and abortive transcription
Wagschal et al. (2012)
Elongation
P-TEFb Heterodimer of CDK9 and cyclin T1. Recruited by Tat to paused RNAPII at TAR RNA.
Stimulates processive transcription by phosphorylating RNAPII, E subunit of NELF and
hSpt5 subunit of DSIF
Yamada et al. (2006) Fujinaga et al.
(2004) Czudnochowski et al. (2012)
Super elongation
complex (SEC)
Complex comprising the factors shown in Fig. 3A. AFF4 and AFF1 organize the assembly of Tat/P-TEFb
into the SEC. ELL proteins stimulate efﬁcient elongation by preventing RNAPII pausing and backtracking.
AF9 and ENL link the SEC to RNAPII
He et al. (2011) Chou et al. (2013)
Tat modiﬁers Histone modifying enzymes that regulate the trans-activating function of Tat by modifying its
P-TEFb or Arg-rich RNA binding regions. These include P/CAF, SIRT1 and LSD1/CoREST
Ott et al. (2011), Lu et al. (2013)
Co-transcriptional processing
SKIP Splicing factor that is recruited by Tat/P-TEFb to the HIV LTR. Associates with activated
spliceosomes within the transcribed region of the proviral gene
Bres et al. (2005)
P-TEFb regulation
7SK snRNP Provides an exchangeable pool of P-TEFb to support transcription of proviral and cellular
genes. Contains 7SK snRNA, HEXIM, LARP7 and MEPCE
Nguyen et al. (2001) Yang et al. (2001)
CDK7 Kinase component of TFIIH. Recently identiﬁed as the CDK9-activating kinase Larochelle et al. (2012)
PPM1A Inactivates CDK9 via dephosphorylation of its activation loop Budhiraja et al. (2012b)
BRD4 Extracts P-TEFb from 7SK snRNP and directs it to cellular genes. Competes with Tat for P-TEFb binding Jang et al. (2005) Bisgrove et al. (2007)
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generated by processing of TAR RNA by microprocessor, the termina-
tion factors Setx and Xrn2, and the 30 to 50 exoribonuclease, Rrp6.
A striking feature of elongation control of the HIV promoter is
that both the restriction of elongation in the absence of Tat and the
efﬁciency of elongation in the presence of Tat is much stronger
than typically seen in cellular promoters (Kim et al., 2011).
Combined surveillance by the negative elongation factor (NELF)
and the DRB sensitivity-inducing factor (DSIF) is used to block
productive elongation in the absence of Tat (Fig. 2). Human DSIF, a
two-subunit complex of hSpt4 and hSpt5, is recruited to newly
Fig. 1. Autoregulation of HIV transcription by Tat via recruitment of P-TEFb from 7SK snRNP. Inactivation of the HIV promoter, mainly due to epigenetic silencing, drives
down Tat to below its threshold levels leading to entry of the provirus into latency, whereas stimulation of transcription initiation induces Tat production. Tat is able to
extract the P-TEFb enzyme complex from the inhibitory 7SK snRNP. Competitive binding of Tat to P-TEFb is favored by signal-dependent modiﬁcation of the activation loop of
the CDK9 subunit.
Fig. 2. Epigenetic regulation and Tat transactivation of proviral transcription. (A) Latent proviruses are characterized by the presence of histone deacetylases (HDACs),
histone methyltransferases (HMTs), and their associated modiﬁcations at Nuc-1 situated around the transcription start site. The deacetylated proviral chromatin becomes a
target for additional silencing via recruitment of polycomb repressive complex-2 (PRC2) which mediates histone methylation. Viral transcripts are inefﬁciently synthesized
but over time there is a build-up of transcriptionally paused polymerase complexes due to the absence of Tat. Escaping RNAP II complexes are forced into abortive
transcription due to NELF. (B) Productive transcription. Efﬁcient assembly of pre-initiation complexes due to chromatin remodeling at the HIV LTR is a signal-dependent
process that is driven by the activity of NF-κB/NFAT and associated co-activators such as p300. The transitioning of paused polymerase into productive elongation requires
kinase activity of P-TEFb. Tat efﬁciently transactivates HIV transcription elongation by recruiting P-TEFb to the paused complex at the TAR hairpin.
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initiated transcription complexes and stimulates capping (Wen
and Shatkin, 1999). Spt5 forms direct contact with nascent RNA as
it emerges from the RNAPII exit site (Cheng and Price, 2008;
Missra and Gilmour, 2010) and facilitates the recruitment of NELF
(Yamaguchi et al., 2002). NELF is able to force premature termina-
tion over a range of several hundred nucleotides (Renner et al.,
2001), limiting the escape of transcription complexes from the
promoter proximal pause site. Pagano et al. (2014) have recently
characterized a consensus NELF subunit E binding element
(CUGAGGA) on nascent cellular RNAs associated with transcrip-
tionally paused genes, which is homologous to a NBE-like element
(CUGGGA) present within the loop region of TAR RNA, and may
lead to enhanced NELF recruitment to the HIV LTR. Thus, knock-
down of NELF by shRNA leads to enhanced basal HIV transcription
and escape from latency (Jadlowsky et al., 2014; Natarajan et al.,
2013; Zhang et al., 2007).
Stimulation of proviral transcription by Tat/P-TEFb
As summarized diagrammatically in Fig. 2B, the switch from
promoter proximal pausing to productive elongation is mediated
by Tat and the positive transcription elongation factor (P-TEFb)
(Herrmann and Rice, 1995; Wei et al., 1998). P-TEFb contains the
CDK9 serine/threonine kinase and cyclin T. Human cyclin T1 is the
only cyclin T that can interact with Tat due to the formation of
Zn2þ-coordinated interactions with the N-terminal cysteine-rich
region of Tat (Cys22-Cys37) (Bieniasz et al., 1998; Fujinaga et al.,
1998; Garber et al., 1998). Crystallographic studies (Tahirov et al.,
2010) have shown that the binding of Tat to CDK9/cyclin T1
(P-TEFb) allows the viral factor to establish partial helical second-
ary structure and induces signiﬁcant conformational changes in
P-TEFb, allowing co-operative recognition and stable binding of Tat
and the cyclin T1 subunit of P-TEFb to TAR (Wei et al., 1998).
Recruitment of P-TEFb at TAR enables CDK9 to phosphorylate
NELF-E and force its dissociation from TAR RNA and the paused
polymerase complex (Fujinaga et al., 2004; Jadlowsky et al., 2014;
Yamaguchi et al., 2002; Zhang et al., 2007). CDK9 also extensively
phosphorylates the CTD of RNAPII mainly at Ser2 and Ser 5 residues
of the heptad repeats (Czudnochowski et al., 2012), and homo-
logous heptapeptide repeats (G-S-Q/R-T-P) of hSpt5 at Thr4 residues
which converts it into a stimulatory elongation factor (Bourgeois
et al., 2002; Yamada et al., 2006). Therefore, the overall effect Tat
and P-TEFb is to remove the blocks to elongation imposed by NELF
and DSIF and to stimulate efﬁcient elongation and co-
transcriptional processing of proviral transcripts. However, because
promoter proximal RNAP II is continuously replaced, there is no loss
of RNAP II from the promoter proximal region (Jadlowsky et al.,
2014).
Tat/P-TEFb is known to remain associated with the elongating
RNAPII machinery throughout transcription (Bourgeois et al.,
2002; Keen et al., 1997; Sobhian et al., 2010) raising the possibility
that it exerts an inﬂuence throughout the transcription cycle. The
temporal and spatial recruitment of transcriptional and RNA
processing factors to actively transcribed genes is guided by the
dynamic changes in the phosphorylation marks on the CTD of
RNAPII that are observed to occur over the course of a transcrip-
tional cycle (Drogat and Hermand, 2012; Perales and Bentley,
2009). Since CDK9 kinase activity is crucial for controlling regular
and alternative RNA splicing and for the recruitment of polyade-
nylation factors at the 30 ends of RNAPII-transcribed genes (Ahn
et al., 2004; Lenasi et al., 2011) it seems likely that Tat can also
inﬂuence these processes. For example, the splicing-associated
c-Ski-interacting protein (SKIP) which had previously been shown
to be a stable component of activated mammalian spliceosome
complexes that are essential for global RNA splicing is recruited by
Tat/P-TEFb to the HIV LTR (Bres et al., 2005). SKIP recruitment
dramatically enhances HIV transcription elongation, alternative
splicing of viral RNA, and Tat-dependent LTR-driven proviral gene
expression. How splicing and transcription termination is mod-
iﬁed by Tat remains one of the unsolved problems in HIV
transcription control.
The Tat/P-TEFb super elongation complex
Although P-TEFb was regarded for many years to be a discrete
elongation factor, recent work has shown that P-TEFb is an integral
component of larger “super elongation complex” (SEC) (Chou
et al., 2013; He et al., 2010; Sobhian et al., 2010) (Fig. 3A). siRNA
knockdowns of individual SEC components strongly inhibits Tat-
dependent LTR-driven reporter gene expression, with knockdown
of the elongation factor ELL2 producing the greatest effect (He
et al., 2010; Sobhian et al., 2010). In actively replicating cells ELL2
is present at limiting levels due to rapid protein degradation by the
polyubiquitination-proteasomal pathway (He et al., 2010; Liu et al.,
2012). Both Tat and the SEC scaffold protein AFF4 prevent the
degradation of ELL2 leading to higher levels of SEC associated with
Fig. 3. The super elongation complex (SEC). (A) Schematic diagram of the SEC. AFF4 (or AFF1) provides a molecular scaffold that organizes the assembly of the SEC. By
preventing the rapid degradation of ELL2, Tat also facilitates SEC assembly at the HIV LTR. The SEC is linked to the paused polymerase complex via an interaction between
ENL or AF9 and the PAF1 subunit. (B) Cartoon and surface renderings of the Tat/P-TEFb 3D structure (Tahirov et al., 2010) superposed onto AFF4/P-TEFb (Schulze-Gahmen
et al., 2013) showing CDK9 T-loop contacts with Tat and the close proximity of Tat to AFF4. The T-loop of CDK9 can potentially make contacts with the N-terminal region of
Tat as reported by Tahirov et al. (2010) and these interactions would be strengthened by the signal-dependent phosphorylation of Ser175. Hydrogen bonding coordination of
the CDK9 Thr186 phosphate moiety by three highly conserved arginine residues reduces the ﬂexibility of the upper T-loop region and may be essential for stabilizing the
CDK9/hCycT1 heterodimer complex.
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P-TEFb (He et al., 2010; Liu et al., 2012). Thus Tat is not only able to
recruit the SEC to the HIV LTR but it is also able to signiﬁcantly
enhance the intracellular fraction of P-TEFb that becomes asso-
ciated with the SEC (He et al., 2010; Sobhian et al., 2010), providing
a complementary mechanism leading to enhanced proviral
reactivation.
AFF4 and its structural homolog AFF1 are large ﬂexible proteins
(1218 and 1163 residues, respectively) that are believed to act as
scaffolds to organize the assembly of the SEC (Chou et al., 2013;
He et al., 2011). Recently a 2.9 Å resolution 3D structure of the
N-terminal CycT1 interacting region of AFF4 (AFF42-73) in complex
with P-TEFb was solved (Schulze-Gahmen et al., 2013), which we
have modeled on the earlier P-TEFb structure (Tahirov et al., 2010),
as shown in Fig. 3B. Tat and AFF4 bind to adjacent sites on hCycT1
and AFF4 can potentially form direct contacts with three Tat
residues (Met1, Lys28, and Phe32). These structural observations
help to explain why acetylation of Tat Lys28 by P/CAF (Bres et al.,
2002; Kiernan et al., 1999) is able to stabilize the Tat/P-TEFb/TAR
ternary complex while mutation of Lys28 (K28A) signiﬁcantly
diminishes the ability of Tat and P-TEFb to trans-activate HIV
in vivo (D'Orso and Frankel, 2009; Kiernan et al., 1999). Thus, Tat
association with AFF4 is highly regulated by post-translational
modiﬁcations and these biochemical pathways help orchestrate
the recruitment of the SEC to the proviral transcription unit.
Establishment of HIV latency
Epigenetic silencing of HIV transcription
HIV preferentially integrates within intragenic regions of
actively transcribed regions of the host genome (Lewinski et al.,
2006). Thus, somewhat surprisingly, the majority of repressed, but
inducible, proviruses are found within the introns of expressed
cellular genes (Lewinski et al., 2005; Shan et al., 2011; Sherrill-Mix
et al., 2013). The implication is that establishment of HIV latency is
regulated independently of the control of the expression of the
host gene into which the provirus has integrated.
Indeed, control of the chromatin structure formed speciﬁcally
on the proviral LTR appears to be a key mechanism leading to
proviral silencing. Independent of the proviral integration site, the
viral 50 LTR is invariably occupied by two precisely positioned
nucleosomes namely, Nuc-0 and Nuc-1 (Verdin et al., 1993). Nuc-1
is situated around the transcription start site and therefore
provides a potential block to the release of promoter proximal
transcription complexes.
A wide array of epigenetic modiﬁcations contribute to the
silencing of latent proviruses. In particular nucleosomes on the 50
LTR of latent proviruses typically display deacteylated histones and
trimethylated histones, a pattern of histone modiﬁcations that is
associated with formation of repressive heterochromatic structures
(Friedman et al., 2011; Keedy et al., 2009). In addition the histone
methyltransferases (HMTs) themselves (SUV39H1, G9a, and EZH2)
have been found to be associated with the latent proviral LTR (du
Chene et al., 2007; Friedman et al., 2011; Imai et al., 2010; Marban
et al., 2007). The dominant histone methyltransferase controlling
HIV latency in T-cells is EZH2 (Friedman et al., 2011), which in
addition to its H3K27 methyltransferase activity, is an important
structural component of polycomb repressive complex 2 (PRC2).
During heterochromatin formation PRC2 offers a binding platform
for multiple chromatin-modifying enzymes including HDACs and
DNA methyltransferase-1 (DNMT1) (Cheng et al., 2011; Tae et al.,
2011; Vire et al., 2006). Methylation of histone H3K9 due to
SUV39H1 and G9a activity additionally stablizes heterochromatin
structures by tethering the chromodomain-containing adaptor
proteins HP1α, -β, and -γ (du Chene et al., 2007).
Numerous trans-acting factors have been found that facilitate
the recruitment of HDACs, PRC2 and other repressor complexes to
the core promoter, suggesting that repression mechanisms may be
both redundant and utilized in different cell types. For example,
the co-operative binding of LSF and YY1 to the LTR allows YY1 to
exert its repressive effect on proviral transcription by interacting
with and recruiting HDAC1 to Nuc-1 (He and Margolis, 2002).
Occupancy of the NF-κB element at the LTR enhancer by p50
homodimers has also been shown to mediate the recruitment of
HDAC1 (Williams et al., 2006). Similarly CBF-1, a key effector of the
Notch signaling pathway, recruits HDACs to LTR of latent pro-
viruses in both infected primary CD4þ T cells and a Jurkat T-cell
model of HIV latency (Tyagi and Karn, 2007; Tyagi et al., 2010).
Finally, the bromodomain protein BRD2 has recently been
reported to mediate repression of the HIV LTR (Boehm et al.,
2013). It is possible that potential BRD2 recruitment to the proviral
LTR, mediated by an interaction with the transcriptional repressor
E2F1, may in turn promote the recruitment of repressor complexes
carrying acetylated lysine residues (Karn, 2013).
DNA methylation at two CpG islands ﬂanking the transcription
start site has also been associated with silencing of the HIV
promoter in latently infected Jurkat T cells and primary CD4þ T
cells (Blazkova et al., 2009; Kauder et al., 2009). However, two
recent studies analyzing the latent viral reservoir of HAART-
treated aviremic patients found very low or no methylation of
the LTR of their HIV-1 DNA suggesting that extensive proviral DNA
methylation is unlikely to be a marker of latent proviruses
(Blazkova et al., 2012; Palacios et al., 2012).
Control of HIV latency by transcriptional interference
An alternative explanation for proviral silencing is that tran-
scriptional interference, characterized by occlusion or dislodge-
ment of transcription initiation or elongation complexes from the
provirus by readthrough transcription of the viral-containing host
gene or termination of host-initiated transcripts at the polyade-
nylation site in the 50 LTR inactivates the provirus (Han et al., 2008;
Lenasi et al., 2008). While there are speciﬁc cases where transcrip-
tional interference has been documented, there is only a slight
preference for proviral integration in the same orientation as the
host gene (63.8% vs 36.2%) in latently infected primary CD4þ T
cells (Shan et al., 2011). Therefore, it seems likely that epigenetic
repression of the provirus always makes a contribution to main-
tenance and establishment of latency.
Host and viral control of P-TEFb activation
Control of Cyclin T1 expression and P-TEFb assembly
Activation of P-TEFb in latently infected T cells is a sequential
process that involves de-repression of hCycT1 expression, phosphor-
ylation of CDK9 at Thr186, assembly of P-TEFb into 7SK snRNP, signal-
dependent and Tat-dependent dissociation of 7SK snRNP, and even-
tually, Tat-dependent recruitment of P-TEFb and the SEC to the HIV
provirus (Fig. 1). Expression of hCycT1 in resting CD4þ T cells is highly
restricted at the post-transcriptional level, and this is likely to be
mediated by several micro-RNAs (Budhiraja et al., 2012a; Chiang et al.,
2012) and direct translational control mechanisms (Hoque et al.,
2011). Levels of hCycT1 protein are elevated very rapidly (within
1 h) upon stimulation of resting T cells with cytokines, protein kinase
C agonists, or ligation of the T cell receptor complex (Mbonye et al.,
2013; Ramakrishnan et al., 2009; Sung and Rice, 2006). Undifferen-
tiated monocytes which, unlike monocyte-derived macrophages and
dendritic cells, are known to be non-permissive to HIV replication also
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show micro-RNA dependent CycT1 restriction (Chiang et al., 2012;
Sung and Rice, 2009).
In contrast to hCycT1, CDK9 is constitutively expressed in
resting T cells and its levels are only modestly increased after
prolonged periods (424 h) of T-cell activation (Ghose et al., 2001;
Mbonye et al., 2013; Ramakrishnan et al., 2009). However, in
resting cells the CDK9 kinase is inactive as a consequence of
dephosphorylation of its regulatory activation loop (T-loop) at the
highly conserved CDK residue Thr186 (Budhiraja et al., 2012a).
Activation of T cells rapidly induces Thr186 phosphorylation of
CDK9 concomitant with the elevation in hCycT1 expression
(Mbonye et al., 2013; Ramakrishnan et al., 2009). Using an elegant
chemical genetic approach Larochelle et al. (2012) have recently
identiﬁed the CDK7 subunit of TFIIH to be the nuclear CDK9-
activating kinase. Similarly, siRNA knockdown studies have iden-
tiﬁed PPM1A as the inactivating phosphatase responsible for
maintaining Thr186 dephosphorylation of CDK9 in resting CD4þ
T cells (Budhiraja et al., 2012b; Wang et al., 2008).
Like other CDKs, CDK9 is activated by binding of the cyclin subunit
which relieves steric blockade at the catalytic cleft by inducing large
conformational changes to the T-loop (Jeffrey et al., 1995; Russo et al.,
1996). The 3D structures of the T-loop phosphorylated CDK9/hCycT1
and CDK2/cyclin A reveal that a hydrogen bonding coordination of the
phosphate moiety by three conserved arginine residues appear to be
essential for stabilizing intermolecular hydrogen bonding interactions
at the CDK/cyclin dimer interface (Fig. 3) (Russo et al., 1996; Tahirov
et al., 2010). Since the phosphorylation of CDK9 at Thr186 is required
to stabilize its heterodimer interactions with hCycT1 (Mbonye et al.,
2013; Russo et al., 1996), the majority of CDK9 in resting T cells is likely
to be present within Hsp90/Cdc37 kinase-speciﬁc chaperone com-
plexes (O'Keeffe et al., 2000).
Regulation of P-TEFb pools by the 7SK RNP complex
Themajority of P-TEFb in activated T-cells is found in the 7SK small
nuclear ribonucleoprotein (snRNP) complex (Kim et al., 2011; Nguyen
et al., 2001; Yang et al., 2001; Yik et al., 2003). The 7SK snRNP provides
an exchangeable pool from which the catalytically competent and
transcriptionally active form of P-TEFb can be readily extracted and
directed to genes. The sequestration of P-TEFb by 7SK snRNP in T-cells
occurs shortly after its signal-dependent biogenesis and requires
Thr186 phosphorylation of CDK9 (Budhiraja et al., 2012a; Chen
et al., 2004; Mbonye et al., 2013).
7SK snRNA provides a scaffold for binding two molecules of P-
TEFb in complex with homo- or heterodimers of the inhibitory
proteins HEXIM1 or HEXIM2 (Li et al., 2005; Peterlin et al., 2012)
(Fig. 1). Within the 7SK snRNP the RNA is protected from nuclease
degradation by the 50 methylphosphate capping enzyme MEPCE
which remains bound at the 50 end, and the La-related protein
LARP7 which binds the polyuridine sequence at the 30 end
(Jeronimo et al., 2007; Krueger et al., 2008; Markert et al., 2008).
Recruitment of P-TEFb by Tat to the provirus and competition
with BRD4
As described above, Tat is able to induce release of P-TEFb from
7SK snRNP (Fig. 1). The Tat-dependent release mechanism is
thought to involve RNA binding by Tat and induction of an RNA
conformational change that poises the viral factor to competitively
displace HEXIM1 from association with P-TEFb (Krueger et al.,
2010; Muniz et al., 2010; Sedore et al., 2007). Therefore, in addition
its classical role as a trans-activator of HIV transcription these
studies have established an important role for Tat as a viral
activator of P-TEFb.
Formation of the Tat/P-TEFb complex is in competition with P-
TEFb binding by the chromatin-binding bromodomain protein BRD4
(Jang et al., 2005; Yang et al., 2005). Like Tat, BRD4 has a well-deﬁned
C-terminal P-TEFb interacting domain (Bisgrove et al., 2007) and can
induce dissociation of P-TEFb from 7SK snRNP (Krueger et al., 2010;
Schroder et al., 2012). Knockdown of BRD4 in the background of a
latent HIV infection, or treatment of latently infected cell lines and
primary T cells with the bromodomain inhibitor JQ1, results in a
robust reactivation of Tat-dependent proviral gene expression
because in the absence of competing BRD4 Tat binding to P-TEFb is
strongly enhanced (Bartholomeeusen et al., 2012; Boehm et al., 2013;
Li et al., 2013; Mbonye et al., 2013; Zhu et al., 2012).
In addition to BRD4, other factors may help recruit P-TEFb to
transcription complexes. Both the DNA-binding transcriptional repres-
sor CTIP2 and the SR-splicing factor SRSF2 have been identiﬁed as
additional regulatory components within 7SK snRNP. CTIP2 mediates
the recruitment of 7SK snRNP to promoters (Cherrier et al., 2013)
while SRSF2 has been proposed to aid transfer of P-TEFb to promoter-
proximally paused RNAPII on cellular genes by binding nascent RNA
transcripts, employing a mechanism analogous to the recruitment of
P-TEFb to TAR by Tat (Ji et al., 2013).
D'Orso and Frankel (2010), D'Orso et al. (2012) have recently
developed the provocative hypothesis that Tat is recruited to the
DNA template before TAR is synthesized. As RNAP II transcribes
through the TAR region there is an exchange that leads to displace-
ment of P-TEFb from the promoter-associated 7SK snRNP to TAR RNA.
Key experiments supporting this idea come from ChIP and ChIP-seq
data showing HEXIM and other 7SK associated proteins bound to
upstream sites on both HIV and cellular promoters (D'Orso and
Frankel, 2010; D'Orso et al., 2012; Ji et al., 2013). However, other
groups, including ourselves, have been unable to detect P-TEFb and
7SK snRNP components upstream of the transcription start site. One
possible explanation for these discrepancies is that D'Orso and Frankel
(2010) performed their experiments in HeLa cells which typically
display a much higher level of basal HIV transcription and less
restriction by heterochromatic structures compared to the latently
infected Jurkat T-cell lines that we have used in our studies. It
therefore possible that the P-TEFb recruitment they observed in the
absence of Tat is due to residual transcription in the HeLa cell system,
perhaps mediated by the high levels of BRD4 that they have found to
be associated with the HIV provirus. It is also possible that the 7SK
RNP complex is only loosely associated with promoters and can only
be detected by ChIP after extensive crosslinking (Ji et al., 2013).
Emergence from latency
Activation of P-TEFb in resting memory T-cells
Activation of latently infected T cells through engagement of
the T-cell receptor (TCR) or stimulation with PKC-agonists results
in the immediate stimulation of processive proviral transcription
(Brooks et al., 2003; Kim et al., 2011; Natarajan et al., 2010). The
early rounds of proviral transcription coincide with the recruit-
ment of P-TEFb to the proviral LTR and requires functional Tat,
even though the short duration of T-cell stimulation is not
sufﬁcient to build-up Tat expression above its undetectable sub-
threshold basal levels (Mbonye et al., 2013).
Recently, we identiﬁed pSer175 as an additional major phospho-
modiﬁcation on the CDK9 T-loop that is induced by TCR and PKC-
agonist stimulation (Mbonye et al., 2013). Signal-dependent Ser175
phosphorylation of CDK9, although not required for Tat binding to
P-TEFb, appears to favor binding of Tat over BRD4 thereby shifting
the equilibrium in favor of Tat. The pSer175 modiﬁcation also
provides an extremely useful marker to identify the transcriptionally
active forms of P-TEFb since it is absent from P-TEFb in the 7SK RNP
complex (Mbonye et al., 2013). In a related study, Fujinaga et al.
(2012) demonstrated that the TCR- or PMA-mediated disassembly of
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7SK sRNP to release P-TEFb requires activation of the protein kinase C
isoform PKC-θ which in turn phosphorylates HEXIM1 protein at
Ser158, which is situated right in the middle of the protein's bipartite
RNA binding sequence. Consequently, the Ser158 phosphorylated
HEXIM1 is unable to bind to 7SK snRNA and is therefore unable to
bind and inhibit P-TEFb. Thus, multiple PTMs on 7SK RNP compo-
nents appear to weaken protein–protein and protein–RNA interac-
tions and shift the equilibrium to favor P-TEFb/Tat complex formation
instead of P-TEFb/BRD4 complex formation. With increasing cycles of
HIV transcription and a progressive elevation in Tat expression, Tat-
dependent dissociation of P-TEFb from 7SK snRNP is expected to
amplify the signal-dependent release of P-TEFb.
Chromatin remodeling and activation of HIV transcription initiation
The absence of cellular transcription initiation factors in the nuclei
of latently infected resting memory CD4þ T cells and non-activated
macrophage lineage cells is another major contributor towards main-
tenance of HIV latency. In the Jurkat T-cell model, TCR stimulation
induces an initial wave of HIV transcription initiation that is largely
dependent on the nuclear localization of NF-κB p65/p50 heterodimer
complexes and their binding to the duplicate NF-κB elements at the
HIV LTR (Kim et al., 2011; Tyagi et al., 2010). Stimulation of latently
infected T lymphocytes and macrophage lineage cells with PKC
agonists or pro-inﬂammatory cytokines also activates HIV transcrip-
tion initiation in a NF-κB p65-dependent manner (Kim et al., 2006;
Nabel and Baltimore, 1987; Williams et al., 2006, 2007).
Nuclear NF-κB p65/p50 directs the recruitment of a co-
activator complex of histone acetyltransferases (HATs) such as
p300/CREB-binding protein (p300/CBP) and p300/CBP-associated
factor (P/CAF) to the HIV LTR (Gerritsen et al., 1997; Perkins et al.,
1997). Acetylation of Nuc-1 appears to a signal allowing recruit-
ment of the chromatin remodeling SWI/SNF complexes. Rafati
et al. (2011) have observed that two functionally distinct sub-
classes of SWI/SNF, BAF and PBAF are exchanged at the LTR.
Maintenance of HIV latency requires BAF, which helps position
the repressive Nuc-1. Upon activation, BAF is lost from the HIV
promoter, while PBAF is selectively recruited to reposition Nuc-1
and facilitate LTR transcription (Rafati et al., 2011).
The NF-κB p65 subunit is itself subject to acetylation by p300/
CBP which serves to maintain it in the nucleus by inhibiting
interaction with IκBα (Chen et al., 2001; Furia et al., 2002).
Deacetylation of p65 by HDAC3 switches off NF-κB-dependent
transcription by allowing IkBα binding and subsequent nuclear
export of p65/p50 (Chen et al., 2001). By contrast, lysine methyla-
tion of p65 stabilizes NF-κB binding to the LTR (Lu et al., 2010).
In primary T-cells NF-κB is typically replaced by NFAT (Bosque
et al., 2011; Bosque and Planelles, 2009; Chan et al., 2013) which is
activated by calcium/calcineurin signaling (Kim et al., 2011). Like
NF-κB p65/p50, NFAT proteins can bind CBP/p300 and recruit its
HAT activity to gene promoters (Garcia-Rodriguez and Rao, 1998).
Surprisingly, NFAT is dispensable in most Jurkat T-cell models
(Chan et al., 2013; Kim et al., 2011). Since NFAT and NF-κB bind in a
mutually exclusive manner to overlapping sites on the proviral
enhancer (Gifﬁn et al., 2003) it seems likely they are used
sequentially during T-cell activation, with NF-κB responsible for
the initial responses and NFAT acting at later times.
Post-transcriptional modiﬁcation of Tat during transcription
The complex interactions between Tat, histone modifying enzymes,
and elongation factors are coordinated through a series of post-
translational modiﬁcations of Tat. In addition to targeting Nuc-1, HATs
are reported to directly modify Tat on lysine residues (Lys50 and
Lys51) that are situated within its arginine-rich TAR RNA binding motif
(ARM) (Col et al., 2001; Kiernan et al., 1999; Ott et al., 1999).
Acetylation of the ARM region is thought to dissociate the binding of
Tat to TAR, and simultaneously reinforce its interactions with chro-
matin modifying transcriptional co-activators by providing acetyl
binding sites for their bromodomains (Lu et al., 2013; Ott et al.,
2011). By contrast, acetylation of Tat by P/CAF at Lys28 situated within
the cysteine-rich region of its activation domain has also been
reported to enhance the association of Tat with P-TEFb and stabilize
the Tat/P-TEFb/TAR ternary complex (Bres et al., 2002; D'Orso and
Frankel, 2009; Kiernan et al., 1999). At the end of the transcription
cycle SIRT1 binds and deacetylates Tat at Lys50 which mediates the
recycling of unacetylated Tat thought to be necessary for subsequent
rounds of viral transcription (Pagans et al., 2005). Following deacetyla-
tion of Tat at the ARM region, monomethylation at Lys51 by Set7/9
bound to TAR enhances Tat-dependent HIV transcription by facilitating
Tat interactions with TAR and recruitment of the host elongation factor
P-TEFb to the RNA (Pagans et al., 2010). Subsequent demethylation of
Lys51 by LSD1/CoREST allows for the re-acetylation of the ARM of Tat
which triggers entry into the TAR-independent phase of proviral
transcription elongation (Sakane et al., 2011). Detailed studies mon-
itoring the kinetics of each of these Tat modiﬁcations will be needed to
provide a fuller understanding of their roles in regulating HIV
transcription.
Stochastic events
Only a very small subset of latent proviruses (o1%) in
peripheral blood becomes reactivated following in vitro ‘max-
imum’ T-cell activation with the mitogen PHA and irradiated
allogeneic PBMCs (Ho et al., 2013). Signiﬁcant genomic sequence
defects (e.g. large internal deletions and APOBEC3G-mediated
hypermutations) account for the lack of reactivation of most of
the non-induced proviruses (88%) (Ho et al., 2013) but the
remaining fraction of non-induced latent proviruses (11%) have
intact sequences, are integrated into actively transcribed regions,
and have been demonstrated in viral reconstruction experiments
to be replication-competent (Ho et al., 2013).
Why only a small fraction of proviruses can be reactivated is
mysterious, and potentially creates a barrier to cure efforts. Within a
clonal population of latently infected Jurkat T-cells, cell-to-cell sto-
chastic ﬂuctuations in the assembly of transcription factor and
chromatin remodeling complexes at the HIV LTR produce occasional
transient bursts of viral transcription in a sub-population of these
cells (Pearson et al., 2008; Singh et al., 2012; Weinberger et al., 2005).
Although the reactivation of latent HIV ex vivo is now deemed to be
inherently stochastic (Ho et al., 2013; Weinberger and Weinberger,
2013), sustained cellular activation is clearly needed in order to
maintain HIV transcription (Kim et al., 2011; Pearson et al., 2008;
Williams et al., 2007). Thus the stochastic nature of proviral reactiva-
tion may contribute to inefﬁcient proviral reactivation during a ﬁrst
round of T-cell activation (Ho et al., 2013).
An alternative, but not exclusive explanation for why certain
subsets of silenced proviruses fail to get reactivated when cells are
stimulated is that epigenetic silencing of HIV-1 results in complex
and heterogenous patterns of histone modiﬁcations and DNA
methylation (Blazkova et al., 2009; Kauder et al., 2009; Pearson
et al., 2008). Interestingly, latent proviruses that reactivate poorly
in response to cellular activators are found to carry higher levels of
H327me3 marks (Friedman et al., 2011).
Summary and perspectives
We believe that the most practical approach to HIV eradication
therapy will be based on using drugs to induce the transcriptional
activity of latent HIV-1 without inducing the polyclonal activation of
non-infected cells (a “shock” phase) since this type of therapy can
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ultimately be delivered in normal clinical settings. Once the virus is
reactivated a “kill” phase will be used to eliminate the induced cells
through existing immune responses, viral cytopathogenicity or
cytotoxic drugs.
The detailed molecular studies described above strongly imply
that effective activation of the entire latent viral pool may
ultimately require a cocktail of drugs that stimulate both tran-
scription initiation and P-TEFb mobilization. Protein kinase C
agonists are a major class of drugs that are able to induce
transcriptional activity of latent HIV-1 (Beans et al., 2013;
Sanchez-Duffhues et al., 2011). All of these drugs are expected to
activate signaling pathways leading to both P-TEFb and NF-κB
mobilization but they tend to lead to global T-cell activation
and associated toxicity. Finding drugs that can selectively activate
P-TEFb in resting T-cells is a major challenge for the ﬁeld.
The second major class of activators that are under investigation
are drugs that induce epigenetic modiﬁcations such as histone
deacetylase (HDAC) inhibitors (e.g. SAHA, panobinostat, rombidepsin)
(Archin et al., 2012; Friedman et al., 2011; Van Lint et al., 1996) and
histone methyltransferase inhibitors (DZNep, BIX01294) (Friedman
et al., 2011; Imai et al., 2010). SAHA has been shown in induce
transient HIV RNA production in patients and is thus the ﬁrst potential
inducer of latent proviruses that has been evaluated as part of the HIV
Cure agenda (Archin et al., 2012). As expected from the mechanisms
described above, transcriptional activation of latent HIV by HDAC
inhibitors occurs independently of NF-κB activity and is associated
with signiﬁcant remodeling of the proviral Nuc-1 region that includes
displacement of Nuc-1, decreased HDAC occupancy and histone
hyperacetylation (He and Margolis, 2002; Kim et al., 2011; Van Lint
et al., 1996). Similarly, treatment of latently infected cells with selective
HMT inhibitors can also reactivate silenced proviruses in various HIV
latency cell line models (Bernhard et al., 2011; Friedman et al., 2011;
Imai et al., 2010). Recently, Bouchat et al. (2012) reported that ex-vivo
treatments of resting CD4þ T cells isolated from HIV-1-infected
individuals with the histone methyltransferase inhibitors chaetocin
or BIX01294 induced virus production to a comparable extent as
treatment with either SAHA or the PKC agonist prostratin.
Although SAHA and other HDAC inhibitors are able to induce viral
RNA transcription in clinical settings it does not typically lead to
release of infectious virions. This may be because although it is able to
allow release of the paused RNAP II it is unable to induce P-TEFb and
ignite a full cycle of viral transcription. The big take home lesson from
the molecular studies of HIV transcription is that efﬁcient viral
reactivation is only seen when there is a reversal of epigenetic blocks
(which is normally accomplished by NFAT or NF-kB activation) and
activation of P-TEFb (which is normally induced through TCR activa-
tion of PKC). It follows that speciﬁc combinations of drugs hitting
these two pathways will be need. We are conﬁdent that new, highly
potent, drug combinations will soon be identiﬁed. The hope for an
HIV cure, only a pipedream a few years ago, remains high.
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